NGD 95-1 oral small molecule inhibitor of neuropeptide Y: Filed IND for a trial to begin in March or April 1996. NGD 95-1 is in development with Pfizer.

Neurogen Corp. (NRGN), Branford, Conn. Product: NGD 95-1 oral small molecule inhibitor of neuropeptide Y Indication: Obesity Status: Filed IND for a trial to begin in March or April 1996. NGD 95-1 is...